CEST MRI in hematoma could be challenging depending on the involvement of iron. This study examined the feasibility of CEST in monitoring ICH and its progression over two weeks. The AREX data supported that the iron-overloading pathology might not significantly attenuate CEST contrast as demonstrated both in vitro and in vivo at 3T. We observed the most significant decrease in rNOE (37%) and APT (47%) contrast in lesions were on day7 and day3, respectively, when compared to contralateral side. This could indicate neuropathologies related to lipid and amide, which could be valuable for ICH diagnosis and treatment planning at 3T.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords